BACTERICIDAL ACTIVITY OF DAPTOMYCIN AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM IN AN INVITRO PHARMACOKINETIC MODEL

被引：11

作者：

BINGEN, E ^{[1
]}

DOIT, C ^{[1
]}

LAMBERTZECHOVSKY, N ^{[1
]}

TOD, M ^{[1
]}

PETITJEAN, O ^{[1
]}

BOURGEOIS, F ^{[1
]}

MARIANIKURKDJIAN, P ^{[1
]}

机构：

[1] HOP AVICENNE,DEPT PHARMACOL TOXICOL,F-93000 BOBIGNY,FRANCE

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 1991年 / 10卷 / 12期

关键词：

D O I：

10.1007/BF01984930

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

A dynamic in vitro model was used to determine the killing kinetics of daptomycin against 15 vancomycin-resistant clinical isolates of Enterococcus faecium. Concentration profiles simulating those observed in serum following administration of both low-dose (2 mg/kg) and high-dose (6 mg/kg) daptomycin were bactericidal within 5.5 and 2.8 h, respectively. In contrast, when albumin was added to the growth medium, the corresponding bacterial killing times were slowed to > 24 h and 7 h; these results suggest that in the clinical setting, daptomycin dosages of approximately 6 mg/kg are required to achieve bactericidal activity against vancomycin-resistant Enterococcus faecium.

引用

页码：1062 / 1065

页数：4

共 18 条

[1] INHIBITION OF PEPTIDOGLYCAN BIOSYNTHESIS IN GRAM-POSITIVE BACTERIA BY LY146032 [J].

ALLEN, NE ;

HOBBS, JN ;

ALBORN, WE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1093-1099

[2] BACTERICIDAL ACTIVITY OF VANCOMYCIN, DAPTOMYCIN, AMPICILLIN AND AMINOGLYCOSIDES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM [J].

BINGEN, E ;

LAMBERTZECHOVSKY, N ;

LECLERCQ, R ;

DOIT, C ;

MARIANIKURKDJIAN, P .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :619-626

[3] DAPTOMYCIN (LY146032) TREATMENT OF EXPERIMENTAL ENTEROCOCCAL ENDOCARDITIS [J].

BUSH, LM ;

BOSCIA, JA ;

KAYE, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (06) :877-881

[4] EARLY TERMINATION OF A PROSPECTIVE, RANDOMIZED TRIAL COMPARING TEICOPLANIN AND FLUCLOXACILLIN FOR TREATING SEVERE STAPHYLOCOCCAL INFECTIONS [J].

CALAIN, P ;

KRAUSE, KH ;

VAUDAUX, P ;

AUCKENTHALER, R ;

LEW, D ;

WALDVOGEL, F ;

HIRSCHEL, B .

JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (02) :187-191

[5]

CHAMBERS HF, 1984, REV INFECTIOUS DIS S, V6, P870

[6] INVITRO AND INVIVO ACTIVITY OF LY 146032, A NEW CYCLIC LIPOPEPTIDE ANTIBIOTIC [J].

ELIOPOULOS, GM ;

WILLEY, S ;

REISZNER, E ;

SPITZER, PG ;

CAPUTO, G ;

MOELLERING, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (04) :532-535

[7] ASSESSMENT OF EFFECTS OF PROTEIN-BINDING ON DAPTOMYCIN AND VANCOMYCIN KILLING OF STAPHYLOCOCCUS-AUREUS BY USING AN INVITRO PHARMACODYNAMIC MODEL [J].

GARRISON, MW ;

VANCEBRYAN, K ;

LARSON, TA ;

TOSCANO, JP ;

ROTSCHAFER, JC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1925-1931

[8]

GARRISON MW, 1989, SO MED J, V82, P141

[9] NEW INVITRO MODEL TO STUDY EFFECT OF ANTIBIOTIC CONCENTRATION AND RATE OF ELIMINATION ON ANTIBACTERIAL ACTIVITY [J].

GRASSO, S ;

MEINARDI, G ;

DECARNERI, I ;

TAMASSIA, V .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 13 (04) :570-576

[10] ANTIBIOTIC-RESISTANCE IN ENTEROCOCCI [J].

GREENWOOD, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (05) :631-635

← 1 2 →